National Institutes of Health, a Component of the US Dept. of Health & Human Services

The United States of America As Represented by the Department of Health

National Institutes of Health

Dyncorp

US Government As Represented by the Secretary of the Army

The Scripps Research Institute

The United States of America As Represented by the Secretary of

St. Jude Children's Research Hospital

Intracel Resources LLC

The Walter Reed Army Institute of Research

American Home Products Corporation

The United States of America

Robert M Chanock

Brian R Murphy

Albert Z Kapikian

Alexander G Pletnev

James E Crowe, Jr

Yasutaka Hoshino

Stephen Whitehead

Joseph R Putnak

Robert H Purcell

Ching-Juh Lai

Joseph E Blaney

Ruhe Men

Louis Potash

Richard G Wyatt

Karen Midthun

Dennis R Burton

Carlos F Barbas, Iii

Jorge Flores

Robert G Webster

Alan R Davis

Kenneth H Eckels

Stephen Alexander Udem

Mark Connors

Michael D Lubeck

Kuo-Hom L Hsu

Michael Bray

Timo Vesikari

Harry B Greenberg

Glenn R Pilkington

Bernard H Selling

Page S Gilmour

Anthony R Kalica

Virginia S Hinshaw

Yi-Ming Zhang

Linda J Saif

Joseph E Blaney, Jr

Val G Hemming

Mario Gorziglia

Irene Peres-Schael

Lone Simonsen

Walter D James

Edward H Bohl

David M Morens

Kenneth W Theil

John R La Montagne

Gregory Prince

Mary Elaine La Montagne, Legal Representative

Stephen S Whitehead

Alexander Pletnev

Albert Kapikian

The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines,

Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus

The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.

The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.

Neutralizing monoclonal antibodies to respiratory syncytial virus

The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human&#xd7; bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest into a multivalent formulation which provides a high degree of infectivity and immunogenicity. Methods and an administration protocol for producing an immunogenic response without producing an increased risk of intussusception are also provided.

Hexavalent bovine rotavirus reassortant composition designed for use in developing countries

The present invention provides vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human&#xd7;bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined in a multivalent formulation which provides a high degree of infectivity and immunogenicity without producing a transient febrile condition. Methods for producing an immunogenic response without producing a transient febrile condition are also provided.

Multivalent human-bovine rotavirus vaccine

The present invention provides compositions for making a medicament and methods for the administration of a vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human x rhesus reassortant rotavirus compositions were made which when administered during the first 7 to about 10 days of life, provided a composition which was non-reactogenic followed by booster immunizations at 16 to 18 weeks or 14 to 20 weeks, up to 1 year of age. The immune response induced by the initial neonatal administration of the live rotavirus vaccine composition protects the infant from the reactogenicity of the composition when administered as a second vaccine dose at or after 2 months of age. Administration of the immunogenic composition also is expected to ablate or significantly diminish the increase in the excess of intussusception observed 3 to 7 days following administration of the initial dose of rotavirus vaccine at about 2 to 4 months.

Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions

Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monoclonal antibodies as well as cell line producing the monoclonal antibodies.

Human neutralizing monoclonal antibodies to respiratory syncytial virus

The present invention provides vaccine compositions of attenuated human rotavirus. More particularly, the attenuated human rotavirus is produced by cold passage and thus contains attenuating mutations which produce virus having a cold-adapted (ca) and temperature sensitive (ts) phenotype. The attenuated strains are used in methods for stimulating the immune system of an individual to induce protection against human rotavirus by administration of the ca attenuated rotavirus.

Attenuated human rotavirus vaccine

Embodiments described herein include full-length infectious cDNA clones of Langat tick-borne flavivirus.

Full-length infectious cDNA clones of tick borne flavivirus

A method for providing passive immmunotherapy to respiratory syncytial virus (RSV) disease in a host is disclosed. The method includes administering to a host a human monoclonal antibody Fab fragment that neutralizes both antigenic subgroup A and subgroup B of respiratory syncytial virus (RSV), or a monoclonal antibody comprising the fragment.

The invention includes a chimeric virus for use in a vaccine preparation having a genome comprising nucleic acid sequences encoding at least one structural protein from one flavivirus and nucleic acid sequences encoding nonstructural protein from another flavivirus. The genome preferably includes mutations within the viral genome that reduce virus virulence and in a particularly preferred embodiment these vaccines are directed to flaviviruses such as dengue virus, tick-borne encephalitis virus and Japanese encephalitis virus. The invention also includes a baculovirus having a recombinant dengue cDNA sequence which encodes: (1) dengue virus capsid protein, pre-matrix protein, envelope glycoprotein and NS1 and NS2a nonstructural proteins or (2) dengue envelope glycoprotein or (3) dengue non-structural proteins NS1 and NS2a. The invention further includes a baculovirus having a recombinant Japanese B encephalitis virus cDNA sequence which encodes the Japanese B encephalitis virus capsid protein, pre-matrix protein, envelope glycoprotein and non-structural proteins NS1 and NS2a. The invention further includes a vaccine and a method to produce that vaccine.

Chimeric and/or growth-restricted flaviviruses

Growing community of inventors

Bethesda, MD, United States of America

Robert M Chanock